A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation

NCT06441084 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

BIOLOGICAL: NCR300 injection

Sponsor

Nuwacell Biotechnologies Co., Ltd.

Collaborators

[object Object]